Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Monday 10 September, 2001

Xenova Group PLC

Research Update

Xenova Group PLC
10 September 2001


FOR IMMEDIATE RELEASE


Xenova Group plc

Anti-Nicotine Addiction Vaccine TA-NIC Enters Phase I Trials

Slough, UK, 10th September 2001 - Xenova Group plc (Nasdaq NM: XNVA; London
Stock Exchange: XEN) today announces that its novel therapeutic vaccine,
TA-NIC, which is being developed for the treatment of nicotine addiction, has
entered Phase I clinical trials.

The Phase I study is a double-blind, randomised, placebo-controlled study to
assess the safety, tolerability and immunogenicity of the TA-NIC vaccine in
both smokers and non-smokers.  The vaccine is administered by intra-muscular
injection.  In the first instance, two different dose levels are to be
investigated in a variety of dosing regimens.

TA-NIC is believed to be the first anti-nicotine addiction vaccine to enter
clinical testing.  TA-NIC uses a novel mode of action whereby it seeks to
prevent nicotine from entering the brain.  Currently available therapies for
nicotine addiction include nicotine replacement therapy, delivered via skin
patches, chewing gum or inhalers or treatment with the nicotine-free drug
bupropion.


Over 1 billion people worldwide smoke tobacco products (World Health
Organisation), resulting in approximately 3 million deaths annually (American
Cancer Society, 1996) from smoking-related disease.  Despite the known health
risks, many people who want to give up smoking cigarettes (or other tobacco
products) find it very difficult to do so, due to the addictive properties of
nicotine and the unpleasant withdrawal symptoms.  Approximately 17 million
smokers in the US alone attempt to quit each year (Center for Disease Control
and Prevention).

TA-NIC is Xenova's second anti-addiction drug candidate to enter clinical
trials.  An anti-cocaine addiction vaccine, TA-CD, is currently in Phase II
clinical development in the US.   Other Xenova products currently undergoing
clinical trials target the treatment of cancer and infectious diseases.


David Oxlade, Xenova's Chief Executive, said: 'Most people who want to stop
smoking find it very hard to do so, even though they may be aware of the risks
involved.  Although at an early stage of development, if TA-NIC can be of
assistance it could have an important contribution to make in reducing the
burdens that smoking imposes.'


                                    -ends-


Contacts
UK
Xenova Group plc                                 Financial Dynamics
Tel: +44 (0)1223 423 413                         Tel: +44 (0)20 7831 3113
John St Clair Roberts: Medical Director          David Yates/Fiona Noblet
Nick Hart: Commercial Director


Also:                                                BMC Communications

(on 10th September only)                             Tel: 001 212 477 9007
Tel: 001 212 477 9007
David Oxlade: Chief Executive Officer
Daniel Abrams: Finance Director
Hilary Reid Evans: Corporate Communications



Notes to Editors

Xenova Group plc's product pipeline focuses principally on the therapeutic
area of cancer, with a secondary focus on infectious, autoimmune and
cardiovascular diseases.  The Group has a well-established track record in the
identification, development and partnering of innovative products and
technologies and has partnerships with a number of major pharmaceutical
companies including Glaxo SmithKline, Lilly, Pfizer, QLT Inc and Celltech.



For further information about Xenova and its products please visit the Xenova
website at www.xenova.co.uk